Company intelligence / Profile preview

Red Leaf Medical

Mississauga, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Red Leaf Medical is advancing UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections (rUTIs) in women, which has shown efficacy and safety in published clinical studies and is awaiting Health Canada approval. They also market fertility and catheter products, including the Health Canada-approved natural health product PROfortil®.[2]

Therapeutic areas: Men's HealthInfectious DiseasesWomen's Health
Modalities: VaccineSmall moleculeDeviceNatural health product
Industry: Biotech

Partnerships

Canadian Antimicrobial Resistance Innovation CouncilBIOTECanada

Beyond the preview

Go deeper on Red Leaf Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Red Leaf Medical.

Explore the full profile